Where Are We With Treatment and Prevention of Heart Failure in Patients Post-Myocardial Infarction?

As a result of the widespread use of reperfusion therapies and secondary prevention over the last 30 years, there has been a dramatic reduction in the risk of mortality and development of heart failure (HF) following acute myocardial infarction (MI). Despite this, the development of chronic HF remains a common occurrence in the days, months, and years following MI. Neurohormonal inhibition remains the mainstay of pharmacologic prevention of HF following MI, with recent trials showing an additive bene fit of a neprilysin inhibitor or a sodium glucose co -transporter 2 inhibitor in reducing the risk of development of HF but no signi ficant effect on mortality. Novel imaging tools may help re fine risk strati fication in high -risk patients and allow greater targeting of preventative therapies in patients most likely to bene fit. Research is ongoing into novel therapies aiming to minimize the degree of myocardial damage and prevention of progressive adverse remodeling following MI. (J Am Coll Cardiol HF 2024;12:1157 -1165) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).